Diassess said that the funds will accelerate development of a flu test for use in the clinic and sustain development of another flu test for use in the home.
The firm anticipates that the award will accelerate the development of its over-the-counter and professional-use influenza and multiplex respiratory pathogen tests.
It anticipates using the funds to complete the development of its first set of diagnostic products, and for a set of clinical studies to obtain regulatory clearance.
The financing will support the company as it works to expand its diagnostic products for non-invasive early detection and monitoring of cancers.
Denmark-based Arcedi would like to commercialize its technology through a major diagnostic company.
The selective whole-genome amplification approach was successfully adapted to Plasmodium vivax, a parasite that is notoriously difficult to culture.
Following a recent acquisition in the proteomics space and several distribution deals, Sygnis has developed its first liquid biopsy product to be launched later this year.
Tataa will distribute the single-cell whole-genome amplification products in Sweden, Norway, Germany, Austria, Slovakia, and the Czech Republic.
The deal gives Australian distributor GeneWorks rights to promote, market, and sell all current and future products in Sygnis' portfolio.
The wholly-owned subsidiary, XCR Dx, will make a portable handheld instrument to use assays built on Fluoresentric's proprietary DNA amplification chemistry.
Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.
NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.
A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.
In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.